Sinopharm Group Jiankun (Beijing) Pharmaceutical Co., Ltd. announced that it will receive funding on October 23, 2019. The transaction will include participation from existing investor China National Medicines Corporation Ltd. (SHSE:600511) and other investor. China National Medicines Corporation Ltd. will invest according to proportion. The transaction has been approved at 17th session of the 7th directorate meeting of China National Medicines Corporation Ltd.